

Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act):

Epigenomics AG sets conversion price

Berlin, Germany, December 13, 2013 – Epigenomics AG (ISIN: DE000A1K0516) announces that its Executive Board today has set the conversion price of the convertible bonds, the respective issuance of which has been published in an ad hoc announcement dated December 3, 2013. As announced in the rights offering, the conversion price was determined according to the XETRA-volume weighted average quotation of Epigenomics' shares during the period from Wednesday December 11, 2013 to Friday, December 13, 2013 (both dates included) and equals EUR 5.87.

The convertible bonds in the aggregate principal amount of up to EUR 2,675,000.00 are currently being offered in a rights offering to those shareholders of Epigenomics AG that held at least one single share in the Company as of December 3, 2013 at an issue price of EUR 100,000 per bond with a principal amount of EUR 107,000. The subscription period for the Company's shareholders ends on December 18, 2013 at 24:00 CET. Convertible bonds not subscribed for during the course of the rights offering by the Company's shareholders will be acquired according to an agreement between Epigenomics and an U.S. American institutional investor by such investor at the same conditions as offered to shareholders.

Each convertible note will be convertible into 107,000 freely tradable shares of Epigenomics' common stock against payment of a conversion premium that equals the product of multiplying (A) the conversion price minus EUR 1.00 with (B) the number of shares to be issued upon conversion (i.e. 107,000). In the event of a conversion of individual or all bonds against payment of a conversion premium, the Company may generate further gross proceeds in the possible amount of up to EUR 13,027,250. Epigenomics has certain further rights to require conversion upon maturity of the convertible bonds or upon FDA approval of its lead product Epi proColon®.

Epigenomics expects that the proceeds from the issuance of these bonds will help to fund the business operations beyond the FDA approval of its lead product, Epi proColon®, a blood-based test for the detection of colorectal cancer. Among others, certain market preparatory activities will be funded by the proceeds from the offering.

Further information regarding the rights offering on the issuance of convertible bonds were published on the Company's website (www.epigenomics.com).

- End of Ad hoc -

Contact Epigenomics AG
Antje Zeise CIRO Manager IR PR Epigenomics AG Phone: +49 (0) 30 24345 386 ir@epigenomics.com

epigenomics

www.epigenomics.com

***Epigenomics' legal disclaimers.** This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.